Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 22:12:10479-10489.
doi: 10.2147/CMAR.S271596. eCollection 2020.

CA125, CEA, CA19-9, and Heteroploid Cells in Ascites Fluid May Help Diagnose Peritoneal Carcinomatosis in Patients with Gastrointestinal and Ovarian Malignancies

Lin Deng #  1 , Shikong Guo #  2 , Hong Li  1 , Xianghui You  1 , Yang Song  1 , Haichuan Su  1
Affiliations

CA125, CEA, CA19-9, and Heteroploid Cells in Ascites Fluid May Help Diagnose Peritoneal Carcinomatosis in Patients with Gastrointestinal and Ovarian Malignancies

Lin Deng et al. Cancer Manag Res. .

Abstract

Background: This study explored the value of ascites and serum CA125, CEA, and CA19-9 levels and ascites DNA ploidy analysis for the diagnosis of peritoneal carcinomatosis (PC) in patients with gastrointestinal and ovarian malignancies, which can cause ascites and may disseminate peritoneally.

Methods: We measured ascites and serum levels of CA125, CEA, CA19-9 and performed an ascites DNA ploidy analysis in 58 patients with PC and 44 patients without PC.

Results: We found that a high expression level of CA125 in ascites fluid was associated with the occurrence of PC in patients with gastrointestinal and ovarian malignancies (P<0.001), and that high CEA and CA19- 9 levels in ascites fluid were associated with PC in patients with gastrointestinal malignancies (P=0.001, P=0.002). But, these tumor marker expression levels in ascites fluid were not significantly associated with the PC stage (P>0.05). We found similar serum levels of CA125, CEA, and CA19-9 between patients with gastrointestinal and ovarian malignancies and PC and those without PC (P>0.05). We found that the presence of three or more cells with heteroploid in the ascites samples was significantly associated with PC in gastrointestinal and ovarian malignancies (P<0.001). In addition, the best ROC curves and highest AUCs were achieved by combining the CA125 level and heteroploid cell analysis results (AUC for gastrointestinal and ovarian malignancies, 0.815, AUC for gastrointestinal malignancies, 0.873). Moreover, the combined ascites CA125 level and result of heteroploid cell analysis provided the best diagnostic sensitivity and specificity for PC (75.9% and 79.5%, respectively, in gastrointestinal and ovarian malignancies; 85.0% and 86.7%, respectively, in gastrointestinal malignancies).

Conclusion: Ascites levels of CA125, CEA, CA19-9, and heteroploid cells can be considered valuable markers for the diagnosis of PC in patients with gastrointestinal and ovarian cancer.

Keywords: ascites; heteroploid cell; peritoneal carcinomatosis; tumor marker.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
ROC of tumor markers and heteroploid cells in the diagnosis of PC in gastrointestinal and ovarian cancer patients.
Figure 2
Figure 2
ROC of tumor markers and heteroploid cells in the diagnosis of PC in gastrointestinal cancer patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chubb SP, Williams RA. Biochemical Analysis of Pleural Fluid and Ascites. Clin Biochem Rev. 2018;39(2):39–50. - PMC - PubMed
    1. Montori G, Coccolini F, Fugazzola P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in ovarian and gastrointestinal peritoneal carcinomatosis: results from a 7-year experience. J Gastrointest Oncol. 2018;9(2):241–253. doi:10.21037/jgo.2017.12.04 - DOI - PMC - PubMed
    1. Lambert LA. Looking up: recent advances in understanding and treating peritoneal carcinomatosis. CA Cancer J Clin. 2015;65(4):284–298. - PubMed
    1. Klaver YL. Peritoneal carcinomatosis of colorectal origin: incidence, prognosis and treatment options. World j Gastroenterology. 2012;18(39):5489–5494. doi:10.3748/wjg.v18.i39.5489 - DOI - PMC - PubMed
    1. van Baal J, van Noorden CJF, Nieuwland R, et al. Development of Peritoneal Carcinomatosis in Epithelial Ovarian Cancer: A Review. j Histochemistry Cytochemistry. 2018;66(2):67–83. doi:10.1369/0022155417742897 - DOI - PMC - PubMed